Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

by James W. Purcell, Han K. Kim, Sonia G. Tanlimco, Minhtam eDoan, Melvin eFox, Peter eLambert, Debra T. Chao, Mien eSho, Keith E. Wilson, Gary C. Starling, Gary C. Starling, Patricia A. Culp
Published 2014-01-01